Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Debt (2016 - 2025)

Ironwood Pharmaceuticals' Total Debt history spans 12 years, with the latest figure at $584.7 million for Q4 2025.

  • For Q4 2025, Total Debt rose 51.86% year-over-year to $584.7 million; the TTM value through Dec 2025 reached $584.7 million, up 51.86%, while the annual FY2025 figure was $584.7 million, 51.86% up from the prior year.
  • Total Debt for Q4 2025 was $584.7 million at Ironwood Pharmaceuticals, roughly flat from $584.5 million in the prior quarter.
  • Across five years, Total Debt topped out at $599.1 million in Q2 2023 and bottomed at $112.9 million in Q2 2021.
  • The 5-year median for Total Debt is $425.0 million (2024), against an average of $394.1 million.
  • The largest annual shift saw Total Debt dropped 29.06% in 2024 before it surged 51.86% in 2025.
  • A 5-year view of Total Debt shows it stood at $116.9 million in 2021, then increased by 3.19% to $120.6 million in 2022, then surged by 314.29% to $499.6 million in 2023, then dropped by 22.93% to $385.0 million in 2024, then skyrocketed by 51.86% to $584.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Total Debt are $584.7 million (Q4 2025), $584.5 million (Q3 2025), and $584.3 million (Q2 2025).